After long-term research, scientists found that targeted alpha therapy has the potential to selectively eliminate HIV infected cells from the central nervous system. The research reveals that a particular human antibody labelled with the alpha emitter bismuth-213 can penetrate the blood brain barrier. Then it can selectively target and destroy HIV-infected cells without influencing non-infected healthy cells. The findings may open a door for new treatment of HIV associated neurocognitive disorders. (CUSABIO provides a lot of proteins, antibodies and kits that associated with HIV. You can get more imformation from http://www.cusabio.com/)
In vitro study, it's found that the new alpha emitter radioactive drug can penetrate a simulated human blood brain barrier without causing damage to it and selectively bind and kill HIV-infected cells residing in the central nervous system. The new technique is based on the unique physical properties of alpha radiation, in particular its high energy and short path length in human tissue, to selectively address and destroy diseased cells while sparing surrounding healthy tissue.
Combined therapy against the virus (cART) enables HIV-positive patients to live much longer. But in the body, the virus persists and continues to cause damage. In particular the treatment of infections of the central nervous system poses a particular challenge as the blood brain barrier limits many cART drugs from reaching effective levels in the brain. For now, about half of all HIV infected people are suffering from mild to moderate neurological disorders.
CUSABIO is always ready to serve researchers in life science and healthcare. You can not only get the biologicals you need, but also read the latest scientific news on CUSABIO's website: http://www.cusabio.com/.
